Summary of Chimeric Therapeutics (CHM) 2025 Extraordinary General Meeting Company Overview - **Company**: Chimeric Therapeutics (CHM) - **Meeting Date**: July 22, 2025 - **Location**: Online meeting hosted from Victoria, Australia Key Points and Arguments Financial Performance - **Fundraising**: Raised $16.6 million during FY 2025, including $5.6 million from a US Family Office [7] - **Debt Management**: The Lindt facility will be fully paid out, marking a significant financial milestone [7] Clinical Development Updates - **CHM CDH 17**: - Trial commenced late last year with five patients treated. - Best result: One patient with stable disease after six months [9] - Manufacturing success: Eight out of eight successful runs, indicating strong operational capabilities [10] - **CHM CoreNK**: - Transitioned to frontline setting for the ADVENT AML study. - Achieved two complete responses with no signs of leukemia in patients [10][14] Resolutions and Voting Outcomes - **Resolution 1**: Ratification of the issuance of 164.3 million first tranche placement shares. - Proxy votes: 86% in favor, 14% against [18] - **Resolution 2**: Approval to issue up to 1.485 billion second tranche placement shares. - Proxy votes: 85% in favor, 15% against [20] - **Resolution 3**: Approval to issue up to 1.65 billion attaching options. - Proxy votes: 79% in favor, 21% against [22] - **Resolution 4**: Approval to issue 25 million adviser options for professional services. - Proxy votes: 79% in favor, 21% against [24] - **Resolution 5A and 5B**: Approval to issue 141.25 million shares and options to Lind. - Proxy votes: 73% in favor, 27% against [26] Meeting Logistics - **Voting Process**: Conducted via a poll, with results to be announced on the ASX later that day [6][30] - **Q&A Session**: No questions were raised during the meeting, indicating either satisfaction with the presented information or a lack of engagement from attendees [29] Additional Important Information - **Management Acknowledgment**: The meeting included acknowledgments of traditional custodians of the land, reflecting the company's commitment to cultural respect [1] - **Operational Efficiency**: Significant headcount and cost reductions were noted, contributing to improved business operations [8] This summary encapsulates the critical aspects of the meeting, highlighting the company's financial health, clinical advancements, and shareholder engagement through resolutions and voting outcomes.